$NTLA

Intellia (NTLA) discussed Q2 2026 updates for lonvo-z in hereditary angioedema, citing a New England Journal manuscript showing a 23-point improvement in quality-of-life score and attack-rate reductions in the lonvo-z arm, with all patients remaining free of long-term prophylaxis as of the data cutoff. The company expects FDA BLA acceptance for lonvo-z by year-end and plans a U.S. launch in H1 next year. It also resumed Q3 Phase III enrollment for nex-z after resolving clinical holds.

Intellia Therapeutics (NASDAQ:NTLA) shares rose 11% to $11.94 after its latest quarterly results. The company reported revenue of $7.7m, about 41% below analyst forecasts, while its statutory loss of $0.80 per share matched expectations. Analysts cut 2026 revenue to $52.3m (down 12%) and raised/kept losses at $3.18 per share, lowering the average price target 8.5% to $23.94.

Intellia Therapeutics (Nasdaq: NTLA) said it granted inducement awards to eight new employees on Aug. 1, 2026 under its 2024 Inducement Plan. The awards total 38,200 shares of time-based restricted stock units, vesting one-third annually over three years, subject to continued service. The grants were approved under Nasdaq Rule 5635(c)(4).

Simply Wall St says Intellia Therapeutics (NTLA) reported Q2 2026 results with a net loss of $106.63 million, or $0.80 per share, and cash of $628.4 million. It also cites positive Phase III lonvo-z data and a resumed Phase III ATTR program after clinical holds were lifted, which may affect its commercialization outlook.

Intellia Therapeutics (NTLA) rose in premarket after Evercore ISI upgraded it to Outperform from Inline. Evercore cited updated results for Intellia’s nex-z rare-disease gene-editing therapy, which it is developing with Regeneron (REGN).

Intellia Therapeutics (Nasdaq: NTLA) reported Q2 2026 EPS of -$0.80, in line with consensus, but collaboration revenue fell to $7.7 million versus an estimated ~$13.0 million. Net loss was $106.6 million. The company said Phase 3 HAELO data for lonvo-z reduced attacks by 87% and expects lonvo-z BLA acceptance in H2 2026 and a U.S. launch in H1 2027. Cash was $628.4 million.

Intellia Therapeutics, Inc. (NTLA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ntla-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates - Positive Phase 3 HAELO clinical data for lonvo-z in HAE presented at EAACI and published in New England Journal of Medicine - Antici

Intellia Therapeutics (Nasdaq: NTLA) reported Q2 2026 results and updates. It said Phase 3 HAELO data for lonvo-z in hereditary angioedema met primary and key secondary endpoints, with an 87% attack reduction vs placebo. Intellia expects FDA BLA acceptance in H2 2026 and a U.S. launch in H1 2027. Cash was $628.4M, funding operations into 2028.

According to Investing.com, Cathie Wood’s ARK ETFs bought Intellia Therapeutics (NTLA) on Monday, totaling over 263,848 shares worth more than $3.5 million via ARKK and ARKG, while selling 50,312 Rocket Lab (RKLB) shares worth over $4 million via ARKQ. NTLA reported positive Phase 3 results for lonvo-z and plans FDA rolling BLA and a potential 1H 2027 launch.

According to Investing.com, Cathie Wood’s ARK ETFs reported May 8, 2026 trades. ARK sold Advanced Micro Devices (AMD) shares worth about $18.8 million and bought CoreWeave (CRWV) for about $14.6 million and Kratos Defense (KTOS) for about $9.6 million. It also bought Kodiak AI (KDK), X-Energy (XE), Cloudflare (NET) and Intellia (NTLA), while selling Rocket Lab (RKLB), Teradyne (TER) and Twist Bioscience (TWST).